BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

4410

507789

JAGSNPHARM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

JAGSONPAL PHARMACEUTICALS performance

Today’s low

Today’s high

₹ 222.05 ₹ 232.84
₹ 224.96

52 week low

52 week high

₹ 110.00 ₹ 328.04
₹ 224.96

Open Price

₹ 226.00

Prev. Close

₹ 227.46

Volume (Shares)

153359.00

Total traded value

₹ 344.99

Upper Circuit

₹ 272.95

Lower Circuit

₹ 181.96

info

JAGSONPAL PHARMACEUTICALS Share Price Update

As of the latest trading session, JAGSONPAL PHARMACEUTICALS share price is currently at ₹ 224.96, which is down by ₹ -2.50 from its previous closing. Today, the stock has fluctuated between ₹ 222.05 and ₹ 232.84. Over the past year, JAGSONPAL PHARMACEUTICALS has achieved a return of 55.55 %. In the last month alone, the return has been 3.64 %. Read More...

JAGSONPAL PHARMACEUTICALS fundamentals


  • Market cap (Cr)

    1,493.40

  • P/E Ratio (TTM)

    28.58

  • Beta

    1.70

  • Book Value / share

    29.69

  • Return on equity

    12.97%

  • EPS (TTM)

    5.49

  • Dividend yield

    0.88%

  • Net profit/quarter (Cr)

    31.99

info icon alternate text
  • Market cap (Cr)

    1,495.00

  • P/E Ratio (TTM)

    28.58

  • Beta

    1.69

  • Book Value / share

    29.69

  • Return on equity

    12.97%

  • EPS (TTM)

    5.49

  • Dividend yield

    0.88%

  • Net profit/quarter (Cr)

    31.99

info icon alternate text

JAGSONPAL PHARMACEUTICALS Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 74.03
Operating Expense 60.86
Net Profit 31.99
Net Profit Margin (%) 43.21
Earnings Per Share (EPS) 4.74
EBITDA 41.34
Effective Tax Rate (%) 17.27
Particulars SEP 2024 (Values in Cr)
Revenue 74.69
Operating Expense 60.98
Net Profit 11.46
Net Profit Margin (%) 15.34
Earnings Per Share (EPS) 4.29
EBITDA 17.93
Effective Tax Rate (%) 25.43
Particulars JUN 2024 (Values in Cr)
Revenue 61.44
Operating Expense 52.49
Net Profit 5.33
Net Profit Margin (%) 8.67
Earnings Per Share (EPS) 1.94
EBITDA 8.40
Effective Tax Rate (%) 25.03
Particulars MAR 2024 (Values in Cr)
Revenue 43.49
Operating Expense 41.44
Net Profit 3.55
Net Profit Margin (%) 8.16
Earnings Per Share (EPS) 1.31
EBITDA 5.16
Effective Tax Rate (%) 21.80
Particulars DEC 2023 (Values in Cr)
Revenue 47.23
Operating Expense 44.48
Net Profit 3.96
Net Profit Margin (%) 8.38
Earnings Per Share (EPS) 1.48
EBITDA 5.92
Effective Tax Rate (%) 25.00
Particulars MAR 2024 (Values in Cr)
Revenue 208.70
Operating Expense 188.11
Net Profit 22.46
Net Profit Margin (%) 10.76
Earnings Per Share (EPS) 8.49
EBITDA 32.33
Effective Tax Rate (%) 24.80
Particulars MAR 2023 (Values in Cr)
Revenue 236.71
Operating Expense 204.18
Net Profit 26.72
Net Profit Margin (%) 11.28
Earnings Per Share (EPS) 10.20
EBITDA 36.43
Effective Tax Rate (%) 23.24
Particulars MAR 2022 (Values in Cr)
Revenue 217.58
Operating Expense 194.37
Net Profit 18.86
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 7.20
EBITDA 28.46
Effective Tax Rate (%) 29.24
Particulars MAR 2021 (Values in Cr)
Revenue 187.95
Operating Expense 170.45
Net Profit 17.06
Net Profit Margin (%) 9.07
Earnings Per Share (EPS) 6.51
EBITDA 23.47
Effective Tax Rate (%) 21.99
Particulars MAR 2020 (Values in Cr)
Revenue 158.57
Operating Expense 151.67
Net Profit 7.87
Net Profit Margin (%) 4.96
Earnings Per Share (EPS) 3.00
EBITDA 11.05
Effective Tax Rate (%) 16.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 70.88
ROE % 12.97
ROCE % 16.89
Total Debt to Total Equity 0.04
EBITDA Margin 15.50
Particulars MAR 2023 (Values in Cr)
Book Value / Share 60.65
ROE % 18.32
ROCE % 23.48
Total Debt to Total Equity 0.02
EBITDA Margin 15.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 50.68
ROE % 15.28
ROCE % 21.14
Total Debt to Total Equity 0.03
EBITDA Margin 13.08
Particulars MAR 2021 (Values in Cr)
Book Value / Share 43.55
ROE % 15.70
ROCE % 19.57
Total Debt to Total Equity 0.05
EBITDA Margin 12.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 39.39
ROE % 7.88
ROCE % 9.53
Total Debt to Total Equity 0.04
EBITDA Margin 6.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 147.93
Total Assets 217.07
Total Liabilities 217.07
Total Equity 187.40
Share Outstanding 26437794
Price to Book Ratio 3.95
Return on Assets (%) 10.34
Return on Capital (%) 11.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 114.62
Total Assets 194.94
Total Liabilities 194.94
Total Equity 158.89
Share Outstanding 26198000
Price to Book Ratio 4.78
Return on Assets (%) 13.70
Return on Capital (%) 16.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.24
Total Assets 164.22
Total Liabilities 164.22
Total Equity 132.75
Share Outstanding 26198000
Price to Book Ratio 6.19
Return on Assets (%) 11.48
Return on Capital (%) 14.2
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.22
Total Assets 164.20
Total Liabilities 164.20
Total Equity 121.92
Share Outstanding 26198000
Price to Book Ratio 1.83
Return on Assets (%) 10.38
Return on Capital (%) 13.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 38.07
Total Assets 146.95
Total Liabilities 146.95
Total Equity 111.03
Share Outstanding 26198000
Price to Book Ratio 0.44
Return on Assets (%) 5.35
Return on Capital (%) 6.8
Particulars MAR 2024 (Values in Cr)
Net Income 29.86
Cash from Operations 43.67
Cash from Investing -24.54
Cash from Financing -8.91
Net change in Cash 1.70
Free Cash Flow 43.92
Particulars MAR 2023 (Values in Cr)
Net Income 34.80
Cash from Operations 53.93
Cash from Investing -57.67
Cash from Financing -0.45
Net change in Cash -11.47
Free Cash Flow 54.24
Particulars MAR 2022 (Values in Cr)
Net Income 26.64
Cash from Operations 13.78
Cash from Investing -25.77
Cash from Financing -17.55
Net change in Cash -36.41
Free Cash Flow 14.83
Particulars MAR 2021 (Values in Cr)
Net Income 21.87
Cash from Operations 31.37
Cash from Investing -2.26
Cash from Financing -6.82
Net change in Cash 19.12
Free Cash Flow 31.84
Particulars MAR 2020 (Values in Cr)
Net Income 9.41
Cash from Operations 12.81
Cash from Investing -10.76
Cash from Financing -0.94
Net change in Cash -0.46
Free Cash Flow 14.88
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2959.45 58.70 29.97 50134.87 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

JAGSONPAL PHARMACEUTICALS Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
224.96 -1.09 redarrow
red-green-graph indicator
6 Bearish
10 Bullish
  • 5 Days 228.90
  • 26 Days 223.20
  • 10 Days 227.40
  • 50 Days 223.40
  • 12 Days 226.60
  • 100 Days 222.20
  • 20 Days 224.10
  • 200 Days 208.90
229.93 PIVOT

First Support

224.48

First Resistance

232.90

Second Support

221.51

Second Resistance

238.35

Third Support

216.06

Third Resistance

241.32

RSI

51.20

ADX

22.29

MACD

3.33

Williams % R

-62.75

Commodity Channel Index (CCI)

31.71

Date

2025-04-30

Week

109002.00

Same Day

38755.00

Month

65992.00

1 Year

1.71

3 Year

1.17

Over 1 Month

3.64%

down

Over 1 Year

55.55%

down

Over 3 Months

-9.61%

down

Over 3 Years

21.88%

down

Over 6 Months

7.81%

down

Over 5 Years

81.82%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

JAGSONPAL PHARMACEUTICALS shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
30.11%
Promoter Holdings
67.77%
FII
2.1%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Aresko Progressive Private Limited 1.3335635E7 (20.08%) Shareholding of Promoter and Promoter Group
Infinity Holdings Sidecar I 1.188825E7 (17.9%) Shareholding of Promoter and Promoter Group
Infinity Holdings 1.103255E7 (16.62%) Shareholding of Promoter and Promoter Group
Infinity Portfolio Holdings 5717950.0 (8.61%) Shareholding of Promoter and Promoter Group
Rajpal Singh Kochhar 3030400.0 (4.56%) Shareholding of Promoter and Promoter Group
Manish Gupta 1656512.0 (2.49%) Public Shareholding
Mukul Mahavir Agrawal 1157557.0 (1.74%) Public Shareholding
Authum Investment And Infrastructure Limited 967965.0 (1.46%) Public Shareholding
Sanjiv Kumar Dudeja 926360.0 (1.4%) Public Shareholding
Lincoln P Coelho 775500.0 (1.17%) Public Shareholding
Infinity Consumer Holdings 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

JAGSONPAL PHARMACEUTICALS corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Aug 2023 5.0 Final 21 Aug 2023 Equity shares
29 Oct 2021 4.0 Interim 01 Nov 2021 Equity shares
22 Sep 2021 1.0 Final 24 Sep 2021 Equity shares
22 Sep 2020 0.5 Final 24 Sep 2020 Equity shares
20 Sep 2019 0.25 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.1 Final 21 Sep 2018 Equity shares
21 Sep 2017 0.1 Final 23 Sep 2017 Equity shares
21 Sep 2016 0.1 Final 23 Sep 2016 Equity shares
21 Sep 2015 0.1 Final 23 Sep 2015 Equity shares
25 Sep 2014 0.5 Final 27 Sep 2014 Equity shares
25 Sep 2013 0.5 Final 27 Sep 2013 Equity shares
21 Sep 2012 5.0 Final 25 Sep 2012 Equity shares
23 Sep 2011 0.5 Final 27 Sep 2011 Equity shares
21 Sep 2010 0.5 Final 23 Sep 2010 Equity shares
23 Sep 2009 0.25 Final 25 Sep 2009 Equity shares
24 Sep 2008 0.1 Final 26 Sep 2008 Equity shares
21 Sep 2007 0.1 Final 25 Sep 2007 Equity shares
26 Sep 2005 0.0 Final 28 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
28 Jul 2004 20 Jul 2004 3:1
Ex-Date Old FV NEW FV Record Date
20 Jul 2004 10.0 5.0 28 Jul 2004
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Aug 2023 5.0 Final 21 Aug 2023 Equity shares
29 Oct 2021 4.0 Interim 01 Nov 2021 Equity shares
22 Sep 2021 1.0 Final 24 Sep 2021 Equity shares
22 Sep 2020 0.5 Final 24 Sep 2020 Equity shares
20 Sep 2019 0.25 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.1 Final 21 Sep 2018 Equity shares
21 Sep 2017 0.1 Final 23 Sep 2017 Equity shares
21 Sep 2016 0.1 Final 23 Sep 2016 Equity shares
21 Sep 2015 0.1 Final 23 Sep 2015 Equity shares
25 Sep 2014 0.5 Final 27 Sep 2014 Equity shares
25 Sep 2013 0.5 Final 27 Sep 2013 Equity shares
21 Sep 2012 5.0 Final 25 Sep 2012 Equity shares
23 Sep 2011 0.5 Final 27 Sep 2011 Equity shares
21 Sep 2010 0.5 Final 23 Sep 2010 Equity shares
23 Sep 2009 0.25 Final 25 Sep 2009 Equity shares
24 Sep 2008 0.1 Final 26 Sep 2008 Equity shares
21 Sep 2007 0.1 Final 25 Sep 2007 Equity shares
26 Sep 2005 0.0 Final 28 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
28 Jul 2004 20 Jul 2004 3:1
Ex-Date Old FV NEW FV Record Date
20 Jul 2004 10.0 5.0 28 Jul 2004

JAGSONPAL PHARMACEUTICALS Share Price

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.

The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.

The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future.

It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.

In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.

On June 27, 2022, Infinity Holdings, an India-focused investment group acquired control over the Company consequent to acquisition of 43.73% of equity capital and became Promoters of the Company. The Company identified several products as part of new launches such as Indocap Gel, Lycored Plus, MemUp, Queezy ER to enhance healthcare professionals' confidence and improve patient outcomes in 2023-24. It acquired the India and Bhutan business of Yash Pharma in May, 2024.

Parent organization Indian Private
NSE symbol JAGSNPHARM
Founded 1978
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The share price of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 224.96 and for BSE is ₹ 225.2.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 14,93.40 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 328.04 and ₹ 110.00 and for BSE is ₹ 328.02 and ₹ 109.42.

How to Buy Jagsonpal Pharmaceuticals Ltd share?

Answer Field

You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 55.55%.

What is the Current Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

Jagsonpal Pharmaceuticals Ltd share price is for NSE ₹ 224.96 & for BSE ₹ 225.2 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE ₹ 14,93.40 & for BSE ₹ 0.0 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Jagsonpal Pharmaceuticals Ltd share is 28.58.

What is the PB ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Jagsonpal Pharmaceuticals Ltd share is 29.69.

How to Buy Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Jagsonpal Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Jagsonpal Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Jagsonpal Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|